BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26182968)

  • 1. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.
    Kiess AP; Minn I; Chen Y; Hobbs R; Sgouros G; Mease RC; Pullambhatla M; Shen CJ; Foss CA; Pomper MG
    J Nucl Med; 2015 Sep; 56(9):1401-1407. PubMed ID: 26182968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.
    Shen CJ; Minn I; Hobbs RF; Chen Y; Josefsson A; Brummet M; Banerjee SR; Brayton CF; Mease RC; Pomper MG; Kiess AP
    Theranostics; 2020; 10(7):2888-2896. PubMed ID: 32194842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
    Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
    Zechmann CM; Afshar-Oromieh A; Armor T; Stubbs JB; Mier W; Hadaschik B; Joyal J; Kopka K; Debus J; Babich JW; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Evaluation of
    Banerjee SR; Minn I; Kumar V; Josefsson A; Lisok A; Brummet M; Chen J; Kiess AP; Baidoo K; Brayton C; Mease RC; Brechbiel M; Sgouros G; Hobbs RF; Pomper MG
    J Nucl Med; 2020 Jan; 61(1):80-88. PubMed ID: 31253744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
    Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM
    Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PSMA-targeted theranostic agent for photodynamic therapy.
    Chen Y; Chatterjee S; Lisok A; Minn I; Pullambhatla M; Wharram B; Wang Y; Jin J; Bhujwalla ZM; Nimmagadda S; Mease RC; Pomper MG
    J Photochem Photobiol B; 2017 Feb; 167():111-116. PubMed ID: 28063300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and preliminary evaluation of
    Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
    Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.
    Mease RC; Dusich CL; Foss CA; Ravert HT; Dannals RF; Seidel J; Prideaux A; Fox JJ; Sgouros G; Kozikowski AP; Pomper MG
    Clin Cancer Res; 2008 May; 14(10):3036-43. PubMed ID: 18483369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Improved
    Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
    J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A low molecular weight PSMA-based fluorescent imaging agent for cancer.
    Chen Y; Dhara S; Banerjee SR; Byun Y; Pullambhatla M; Mease RC; Pomper MG
    Biochem Biophys Res Commun; 2009 Dec; 390(3):624-9. PubMed ID: 19818734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
    Yao X; Zha Z; Ploessl K; Choi SR; Zhao R; Alexoff D; Zhu L; Kung HF
    Bioorg Med Chem; 2020 Mar; 28(5):115319. PubMed ID: 32001090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.
    Meher N; Seo K; Wang S; Bidkar AP; Fogarty M; Dhrona S; Huang X; Tang R; Blaha C; Evans MJ; Raleigh DR; Jun YW; VanBrocklin HF; Desai TA; Wilson DM; Ozawa T; Flavell RR
    ACS Appl Mater Interfaces; 2021 Nov; 13(46):54739-54752. PubMed ID: 34752058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A PSMA Ligand Labeled with Cobalt-55 for PET Imaging of Prostate Cancer.
    Dam JH; Olsen BB; Baun C; Høilund-Carlsen PF; Thisgaard H
    Mol Imaging Biol; 2017 Dec; 19(6):915-922. PubMed ID: 28924629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hetero-bivalent agents targeting FAP and PSMA.
    Boinapally S; Lisok A; Lofland G; Minn I; Yan Y; Jiang Z; Shin MJ; Merino VF; Zheng L; Brayton C; Pomper MG; Banerjee SR
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4369-4381. PubMed ID: 35965291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [
    Roy J; White ME; Basuli F; Opina ACL; Wong K; Riba M; Ton AT; Zhang X; Jansson KH; Edmondson E; Butcher D; Lin FI; Choyke PL; Kelly K; Jagoda EM
    Mol Imaging Biol; 2021 Oct; 23(5):745-755. PubMed ID: 33891265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.